Of clinical importance, thiazolidinediones (TZDs), a major class of drugs for the treatment of type 2 diabetes (T2D), improve whole-body insulin sensitivity through the activation of PPARγ. This evidence concerns the gene INS and type 2 diabetes mellitus.